News & Events about Neoleukin Therapeutics Inc.
Globe Newswire
6 months ago
Targeted, precision-tuned agonist of IL-2 receptor selectively expands regulatory T cellsSEATTLE, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., Neoleukin (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics...
Ticker Report
6 months ago
HC Wainwright cut shares of Neoleukin Therapeutics (NASDAQ:NLTX Get Rating) from a buy rating to a neutral rating in a research report report published on Wednesday morning, The Fly reports. HC Wainwright also issued estimates for Neoleukin Therapeutics Q2 2023 earnings at ($0.17) EPS...
Globe Newswire
7 months ago
SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., Neoleukin (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced an oral presentation at the upcoming American Society of Hematology (ASH...
Zacks Investment Research cut shares of Neoleukin Therapeutics (NASDAQ:NLTX Get Rating) from a buy rating to a hold rating in a research report report published on Friday morning, Zacks.com reports. According to Zacks, Neoleukin Therapeutics Inc. is a biopharmaceutical company. It is engaged in ...
- NL-201 demonstrates antitumor activity in preclinical B-cell lymphoma models - - NL-201 synergizes with radiation therapy to generate potent, antitumor immunity - SEATTLE, April 13, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., Neoleukin (NASDAQ:NLTX), a biopharmaceutical company ...